AXSOME THERAPEUTICS, INC. (AXSM) Operating Margin
- Operating margin · 12 months: Value -23.96%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -23.96% | Operating income / revenue. Period ending 2026-06-30. $-186.07M ÷ $776.57M × 100 ≈ -23.96% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -186.07M USD | Operating Income (Loss) |
| Revenue | 776.57M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 187.86M USD | Research and Development Expense |
| Selling, general and administration | 712.66M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-186.07M | $776.57M | (m) | $187.86M | $712.66M | -23.96% |
| 2026-03-31 | $-173.14M | $708.24M | (m) | $191.17M | $634.81M | -24.45% |
| 2025-12-31 | $-166.76M | $638.50M | (m) | $183.28M | $570.60M | -26.12% |
| 2025-09-30 | $-212.42M | $561.26M | (m) | $189.49M | $514.57M | -37.85% |
| 2025-06-30 | $-228.94M | $495.03M | (m) | $194.72M | $459.90M | -46.25% |
| 2025-03-31 | $-270.27M | $432.16M | (m) | $195.03M | $433.18M | -62.54% |
| 2024-12-31 | $-280.56M | $385.69M | (m) | $187.08M | $411.36M | -72.74% |
| 2024-09-30 | $-306.22M | $338.46M | (m) | $162.87M | $384.90M | -90.48% |
| 2024-06-30 | $-305.71M | $291.49M | (m) | $146.25M | $372.52M | -104.88% |
| 2024-03-31 | $-292.73M | $251.02M | (m) | $116.98M | $347.90M | -116.61% |
| 2023-12-31 | $-231.82M | $270.60M | (m) | $97.94M | $323.12M | -85.67% |
| 2023-09-30 | $-193.47M | $223.44M | (m) | $81.83M | $297.81M | -86.59% |
| 2023-06-30 | $-173.76M | $182.49M | (m) | $67.94M | $255.52M | -95.21% |
| 2023-03-31 | $-147.88M | $144.61M | (m) | $63.16M | $207.74M | -102.26% |
| 2022-12-31 | $-179.80M | $50.04M | (m) | $57.95M | $159.25M | -359.33% |
| 2022-09-30 | $-152.49M | (m) | (m) | $57.04M | (m) | (m) |
| 2022-06-30 | $-143.49M | (m) | (m) | $55.34M | (m) | (m) |
| 2022-03-31 | $-135.15M | (m) | (m) | $54.05M | (m) | (m) |
| 2021-12-31 | $-124.71M | (m) | (m) | $58.06M | (m) | (m) |
| 2021-09-30 | $-119.84M | (m) | (m) | $61.66M | (m) | (m) |
| 2021-06-30 | $-107.56M | (m) | (m) | $63.28M | (m) | (m) |
| 2021-03-31 | $-94.49M | (m) | (m) | $59.32M | (m) | (m) |
| 2020-12-31 | $-99.14M | (m) | (m) | $70.24M | (m) | (m) |
| 2020-09-30 | $-95.83M | (m) | (m) | $72.07M | (m) | (m) |
| 2020-06-30 | $-93.65M | (m) | (m) | $73.11M | (m) | (m) |
| 2020-03-31 | $-89.32M | (m) | (m) | $73.57M | (m) | (m) |
| 2019-12-31 | $-67.25M | (m) | (m) | $53.65M | (m) | (m) |
| 2019-09-30 | $-52.27M | (m) | (m) | $41.59M | (m) | (m) |
| 2019-06-30 | $-41.56M | (m) | (m) | $31.80M | (m) | (m) |
| 2019-03-31 | $-36.10M | (m) | (m) | $26.35M | (m) | (m) |
| 2018-12-31 | $-32.85M | (m) | (m) | $23.50M | (m) | (m) |
| 2018-09-30 | $-29.84M | (m) | (m) | $20.84M | (m) | (m) |
| 2018-06-30 | $-27.89M | (m) | (m) | $19.27M | (m) | (m) |
| 2018-03-31 | $-26.66M | (m) | (m) | $18.72M | (m) | (m) |
| 2017-12-31 | $-27.16M | (m) | (m) | $19.96M | (m) | (m) |
| 2017-09-30 | $-28.35M | (m) | (m) | $21.27M | (m) | (m) |
| 2017-06-30 | $-29.26M | (m) | (m) | $22.37M | (m) | (m) |
| 2017-03-31 | $-29.33M | (m) | (m) | $22.66M | (m) | (m) |
| 2016-12-31 | $-27.54M | (m) | (m) | $21.20M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-9.20M | (m) | (m) | $6.78M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-5.67M | (m) | (m) | $4.28M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |